Two major food categories have joined DOLCE

Zwingenberg, Potsdam (Germany) and Lestrem (France), November 16, 2016: The bioeconomy company BRAIN AG (ISIN DE0005203947 / WKN 520394), the natural product specialist AnalytiCon Discovery GmbH and Roquette, a global leader in specialty food ingredients from plant-based raw materials, announced today that two major food categories have already joined the recently published strategic DOLCE partnership. This newly created partnership was started in August 2016 and offers consumer product goods companies a platform providing expert know-how to develop and produce natural sweetening solutions in order to achieve sugar- and calorie reduction in diverse food and beverage categories.

The three DOLCE research partners together have been in discussions with many of the global Fortune 500 consumer product goods companies ("CPGCs") representing the largest food and beverage brands.

Already two food categories, namely "morning foods" and "snacks", have joined the program and committed to DOLCE. The interest of such CPGC members is to integrate newly developed, innovative, and all natural DOLCE sweet solutions into their end products to address the critical need for sugar reduction in the global nutrition market. Further financial details are not disclosed.

With the recent win of two global food categories, the DOLCE initiative proves that it can cover the complete value chain from the discovery & development (BRAIN and AnalytiCon) over the formulation & production (Roquette) to the marketing & sales (CPGCs) of novel, natural sweet solutions for expanded food and beverage segments. Further CPGCs are invited to join the DOLCE Program as members in selected application fields.

According to a study of Lux Research from January 2016, sugar substitutes today account for 22% of the total sweetener market, yet natural sweetener alternatives represent only 1%. Along with trends towards natural and healthy ingredients, these natural alternatives have the potential to replace between 2% and 25% of total sucrose across product categories like bakery and cereal, beverage, and confection.

+++ENDS+++

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en

Contact:

B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de


Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.